Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
10/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
22/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
29/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

04/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi
26/11/18	TxCell : près de sept millions d'actions apportées à l'OPAS
23/11/18	TXCell : Sangamo Therapeutics dépasse les 90%
16/11/18	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	-3.30%	+2.97%	+54.99%	+104.15%	74.18B
ARGENX SE	-0.12%	-3.82%	+34.21%	+74.94%	59.55B
INSMED INCORPORATED	+1.45%	-4.00%	-15.59%	+361.68%	25.84B
BIONTECH SE	+0.33%	-0.08%	-1.17%	-4.40%	24.73B
GENMAB A/S	-1.05%	+1.07%	+21.45%	-10.04%	20.87B
PHARMAESSENTIA CORPORATION	-1.70%	-4.15%	+147.82%	+325.69%	15.32B
EXELIXIS, INC.	+1.23%	-2.38%	+46.75%	+161.57%	14.06B
SUMMIT THERAPEUTICS INC.	-0.55%	-8.58%	-20.98%	+743.75%	13.12B
MADRIGAL PHARMACEUTICALS, INC.	+0.47%	-4.25%	+19.88%	+239.00%	11.85B
Average	-0.33%	-0.80%	+31.93%	+221.81%	28.84B
Weighted average by Cap.	-0.93%	-0.22%	+34.73%	+158.25%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile